| Indicators | Browse All

ImageneBio, Inc. (IMA)

Healthcare | Biotechnology | San Diego, United States | NasdaqCM
6.11 USD +0.20 (3.384%) ⇧ (July 13, 2026, 4 p.m. EDT)
After hours: 6.11

Short-term:★☆☆☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 6:03 a.m. EDT

The immediate outlook is severely clouded by a massive liquidity crisis. While the company recently secured $30 million in private funding, the stock is trading at a fraction of its book value ($5.91 vs $10.93) because the market is pricing in an imminent bankruptcy scenario driven by relentless cash burn. Operating cash flow is draining at -$55 million annually, and the free cash flow is nearly -$27 million, meaning the recent capital raise is merely extending a runway that is already critically short. The balance sheet, while technically showing a high current ratio due to cash reserves, cannot sustain these burn rates without further dilution or a successful clinical trial outcome, neither of which is guaranteed. Fundamentally, the business is deteriorating rapidly; the stock has lost over 90% of its value over the last four years, with the most recent annual performance showing another double-digit decline. This is not a value opportunity; it is a distressed asset where the probability of total loss outweighs the speculative upside of a potential drug approval.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.030460
MSTL0.031507
MSTL_1260.042027
AutoTheta0.049976
MSTL_900.067882
MSTL_90_1260.076977
AutoARIMA0.119987

Forecast horizon: 60 days | Selected: AutoETS

Forecast Reliability
Score 41%
H-stat 1.30
Ljung-Box p 0.000
Jarque-Bera p 0.160
Excess Kurtosis -0.42
Attribute Value
Sector Healthcare
Debt to Equity Ratio 1.959
Market Cap 68,915,488
Forward P/E -1.54
Previous Name Inmagene Biopharmaceuticals Co. Ltd.
Website https://www.inmagenebio.com

Info Dump

Attribute Value
52 Week Change -0.6405109
Address1 12,526 High Bluff Drive
Address2 Suite 345
All Time High 451.32
All Time Low 3.94
Ask 7.66
Ask Size 2
Audit Risk 10
Average Daily Volume10 Day 8,310
Average Daily Volume3 Month 45,309
Average Volume 45,309
Average Volume10Days 8,310
Bid 4.45
Bid Size 2
Board Risk 8
Book Value 10.934
City San Diego
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 10
Country United States
Crypto Tradeable 0
Currency USD
Current Price 6.11
Current Ratio 18.391
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 6.2999
Day Low 5.9001
Debt To Equity 1.959
Display Name ImageneBio
Ebitda -54,038,248
Ebitda Margins 0.0
Enterprise To Ebitda 0.849
Enterprise Value -45,876,516
Eps Current Year -4.10333
Eps Forward -3.98
Eps Trailing Twelve Months -4.8
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 5.7563
Fifty Day Average Change 0.35370016
Fifty Day Average Change Percent 0.06144575
Fifty Two Week Change Percent -64.051094
Fifty Two Week High 18.0
Fifty Two Week High Change -11.889999
Fifty Two Week High Change Percent -0.66055554
Fifty Two Week Low 3.94
Fifty Two Week Low Change 2.17
Fifty Two Week Low Change Percent 0.55076146
Fifty Two Week Range 3.94 - 18.0
Financial Currency USD
First Trade Date Milliseconds 1,616,765,400,000
Float Shares 5,804,579
Forward Eps -3.98
Forward P E -1.5351759
Free Cashflow -27,264,376
Full Exchange Name NasdaqCM
Full Time Employees 17
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,782,864,000
Gross Margins 0.0
Gross Profits 0
Has Pre Post Market Data 1
Held Percent Insiders 0.11261
Held Percent Institutions 0.4816
Implied Shares Outstanding 11,279,130
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,753,660,800
Last Split Factor 1:12
Long Business Summary ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Long Name ImageneBio, Inc.
Market us_market
Market Cap 68,915,488
Market State PREPRE
Max Age 86,400
Message Board Id finmb_689254445
Most Recent Quarter 1,774,915,200
Name Change Date 2,026-07-13
Net Income To Common -53,886,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 68,577,110
Number Of Analyst Opinions 1
Open 5.98
Operating Cashflow -55,414,000
Operating Margins 0.0
Overall Risk 10
Payout Ratio 0.0
Phone 858 345 6265
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 6.11
Post Market Time 1,783,973,404
Prev Name Inmagene Biopharmaceuticals Co. Ltd.
Previous Close 5.91
Price Eps Current Year -1.4890345
Price Hint 2
Price To Book 0.5588074
Price To Sales Trailing12 Months Infinity
Profit Margins 0.0
Quick Ratio 17.668
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.2
Regular Market Change Percent 3.3841
Regular Market Day High 6.2999
Regular Market Day Low 5.9001
Regular Market Day Range 5.9001 - 6.2999
Regular Market Open 5.98
Regular Market Previous Close 5.91
Regular Market Price 6.11
Regular Market Time 1,783,972,801
Regular Market Volume 12,527
Return On Assets -0.45615003
Return On Equity -0.86155
Revenue Per Share 0.0
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 10
Shares Outstanding 11,279,130
Shares Percent Shares Out 0.0359
Shares Short 404,370
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 445,327
Short Name ImageneBio, Inc.
Short Percent Of Float 0.0364
Short Ratio 27.06
Source Interval 15
State CA
Symbol IMA
Target High Price 24.0
Target Low Price 24.0
Target Mean Price 24.0
Target Median Price 24.0
Total Cash 117,208,000
Total Cash Per Share 10.392
Total Debt 2,416,000
Total Revenue 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -4.8
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 6.54581
Two Hundred Day Average Change -0.4358101
Two Hundred Day Average Change Percent -0.06657848
Type Disp Equity
Volume 12,527
Website https://www.inmagenebio.com
Zip 92,130